This Government Contract opportunity from Department Of Health And Human Services was posted on May 18, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

In Vivo Efficacy Testing for Medical Countermeasures

Closed

Federal

Submission Closed06/02/2026, 07:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Canada

Scientific Data Analysis & Software Tool Development for JWSTThe contract involves the development and ongoing maintenance of software tools specifically designed for the calibration of NIRISS data, pipeline processing, and support of scientific operations related to the James Webb Space Telescope (JWST). This subcontract opportunity, issued by the National Research Council of Canada under the Government of Canada, seeks expertise in scientific data analysis and software tool development to enhance JWST's data handling capabilities. The work is to be performed in British Columbia and is associated with NAICS code 541714, indicating a focus on research and development in the physical, engineering, and life sciences. The solicitation was posted on June 15, 2026, with a response deadline of June 30, 2026. Although specific details such as set-aside types, organization type, or a direct point of contact are not provided, interested parties are encouraged to refer to the official tender notice link for more information. The contract emphasizes advanced software solutions to support scientific missions, ensuring the effective processing and analysis of space telescope data crucial for ongoing research.

National Research Council of Canada

POSTED

DEADLINE

International Agricultural Research Program DesignThe contract entails the design and structuring of a comprehensive international agricultural research program that aligns with the priorities of the Foreign Agricultural Service under the Department of Agriculture. It involves developing clear objectives, detailed methodologies, and expected outcomes aimed at advancing agricultural research on a global scale. The scope emphasizes strategic planning to address international agricultural challenges while supporting USDA-FAS goals to enhance trade, sustainability, and food security. This subcontract, carrying the NAICS code 541714, was posted on June 15, 2026, with a response deadline of August 14, 2026. While specific details such as the location of performance and contact information are not provided, the focus is on crafting a program that integrates scientific research with policy priorities to foster innovation and collaboration in international agriculture. The resulting program is expected to facilitate informed decision-making and promote economic opportunities within the global agricultural sector.

Foreign Agricultural Service

POSTED

DEADLINE

TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.

Triad - DOE Contractor

POSTED

DEADLINE

Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.

Defense Health Agency

POSTED

DEADLINE

Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT)The contract seeks to develop a universal, modular synthetic biology platform designed to create advanced microbial chassis with customizable, programmable functions. Initially focusing on toxin removal as a proof-of-concept for managing chronic diseases, this platform is intended to be versatile and scalable, applicable across various fields including environmental cleanup, biomanufacturing, agriculture, comprehensive medical applications, and therapeutic research. The aim is to produce a stable, reliable microbial system that can be easily reprogrammed to tackle a wide range of challenges beyond the initial health-related use case. This solicitation is issued by the Advanced Research Projects Agency for Health (ARPA-H) under the Department of Health and Human Services, with a total small business set-aside status encouraging participation from companies with fewer than 500 employees. The opportunity was posted in June 2026, with responses due within a month, targeting innovation under the Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT) initiative. The effort embodies a cross-sector approach to synthetic biology, seeking transformative impacts across health and industry by enabling next-generation living systems capable of adaptive and programmable biological functions.

Arpa-H

POSTED

6 days ago

DEADLINE

in 23 days

AI Contract Overview

This contract involves conducting in vivo efficacy studies to assess candidate medical countermeasures aimed at treating Acute Radiation Syndrome (ARS) and Delayed Effects of Acute Radiation Exposure (DEARE). The studies will focus on evaluating dose-response relationships and survival endpoints to determine the effectiveness of these treatments. The work is commissioned by the National Institutes of Health, specifically the National Institute of Allergy and Infectious Diseases (NIAID), under the Department of Health and Human Services. The contract is structured as a subcontract and is categorized under the NAICS code 541714, which pertains to research and development in biotechnology. The solicitation was posted on May 18, 2026, with a response deadline of June 2, 2026. Specific details regarding the location of performance and point of contact have not been provided. The contract emphasizes the importance of rigorous testing to support the development of medical countermeasures for radiation exposure, reflecting a critical public health initiative.

General Info

Conduct in vivo studies evaluating medical countermeasures for radiation syndrome, commissioned by NIH/NIAID.

Agency

Department Of Health And Human Services → National Institutes Of Health Niaid

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

MD, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedMay 18

subcontract

Response DeadlineJun 2

Deadline has passed

Submission Closed

06/02/2026, 07:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid

ContactsNo contacts available

OfficeN/A

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health Niaid

Office AddressN/A

ContactsNo contact information available

Full Description

Conduct in vivo efficacy studies to evaluate candidate MCMs for treating ARS and DEARE, including dose-response assessments and survival endpoints.